🔎 Trials Near Me

ホーム › 神経芽腫 › ミズーリ州

ミズーリ州における神経芽腫の臨床試験

ミズーリ州内の拠点で、神経芽腫に関する10件の研究が参加者を募集しています。

ミズーリ州内の都市

公式研究テキスト（英語）

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • University of Missouri Children's Hospital, Columbia
  • Children's Mercy Hospitals and Clinics, Kansas City
  • Washington University School of Medicine, St Louis
  • 他1件
被験者募集中第3相
30歳以下 · 全性別 · 2026/10/02更新 · NCT06172296

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Mercy Hospital ( Site 1024), Kansas City
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  • Cardinal Glennon Children's Medical Center, St Louis
被験者募集中第2相
22歳以下 · 全性別 · 2026/09/04更新 · NCT02559778

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

  • Cardinal Glennon Children's Medical Center, St Louis
被験者募集中第1/2相
26歳以下 · 全性別 · 2026/09/03更新 · NCT06465199

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Children's Mercy Hospitals and Clinics, Kansas City
  • Cardinal Glennon Children's Medical Center, St Louis
被験者募集中第1/2相
30歳以下 · 全性別 · 2026/09/03更新 · NCT06541262

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

  • Cardinal Glennon Children's Medical Center, St Louis
被験者募集中第2相
1歳〜21歳 · 全性別 · 2026/09/03更新 · NCT06540963

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • University of Missouri Children's Hospital, Columbia
  • Children's Mercy Hospitals and Clinics, Kansas City
  • Washington University School of Medicine, St Louis
  • 他1件
被験者募集中第3相
365 Days – 30 Years · 全性別 · 2026/08/25更新 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Washington University School of Medicine, St Louis
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  • Cardinal Glennon Children's Hospital, St Louis
被験者募集中第2相
12 Months – 21 Years · 全性別 · 2026/08/12更新 · NCT05489887

SPEARHEAD-3 Pediatric Study

  • Washington University, St Louis
被験者募集中第1/2相
2歳〜21歳 · 全性別 · 2026/08/11更新 · NCT05642455

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。